Regorafenib receives Priority Review for colorectal cancer
14:29 EDT 28 Jun 2012 | BioCentury
FDA accepted and granted Priority Review to an NDA from Bayer AG (Xetra:BAYN) for regorafenib to treat metastatic colorectal cancer. The company submitted the application at the end of April; a six-month Priority Review would set the PDUFA date aroun..
Original Article: Regorafenib receives Priority Review for colorectal cancer
More From BioPortfolio on "Regorafenib receives Priority Review for colorectal cancer"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
